SAT0434 Osteoarthritis Related Effusion: Follow up of Pain and Fluid Thickness after Treatment with Spironolactone. A Prospective Study
| Autor: | Ahmed M. Elsaman, Sarah Ohrndorf, Ahmed R. Radwan |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
education.field_of_study medicine.diagnostic_test business.industry Visual analogue scale Immunology Population Physical examination Osteoarthritis Placebo medicine.disease General Biochemistry Genetics and Molecular Biology Surgery Rheumatology Effusion Anesthesia Knee effusion Immunology and Allergy Medicine medicine.symptom business Prospective cohort study education |
| Zdroj: | Annals of the Rheumatic Diseases. 75:828.2-828 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Background Osteoarthritis (OA) is a group of mechanical disorders leading to joint components degradation, including articular cartilage and subchondral bone. Incidence and prevalence of knee OA is rising by increasing average age of general population and increasing obesity (1). Treatment of knee effusion includes: rest, cold compresses, elevation, NSAIDS and aspiration (2). Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. (3). Objectives Evaulation of low dose Spironolactone as a treatment for osteoarthritis related effusion using ultrasound and pain VAS. Methods This study was carried out on 200 patients who aged 40 years or above with unilateral knee effusion related to osteoarthritis based on clinical examination, musculoskeletal ultrasonography (US) and synovial fluid analysis. Group 1 consisted of 50 patients received spironolactone 25 mg daily for 2 weeks, in group 2; 50 Patients took Ibuprofen 1200 mg daily for two weeks, in group 3; 50 patients used cold compresses two times daily for two weeks, and in group 4; 50 patients received placebo for the same time duration. Visual analog scale (VAS) for pain was done to the study participant at time 0 (baseline), after 2 weeks and after 4 weeks. Results The mean age of the participants was 51.2±8.1 years. The mean duration of effusion was 16.5±3.6 days. In group 1, 66% had complete improvement, 20% partial improvement and 14% no response. In group 2, 24% had complete improvement, 12% partial improvement and 64% no response. In group 3, 28% had complete improvement, 14% partial improvement and 58% no response. In group 4, 6% had complete improvement, 10% partial improvement and 84% no response. VAS had a strong relation to fluid thickness as it decreased with the improvement of effusion and increased again among those patients who developed recurrence after 4 weeks. Conclusions Low dose spironolactone is a safe and effective medical treatment for OA related knee effusion, especially in mild and moderate knee effusion. References Abraham AM, Pearce MS, Mann KD, Francis RM, Birrell F. Population prevalence of ultrasound features of osteoarthritis in the hand, knee and hip at age 63 years: the Newcastle thousand families birth cohort. BMC Musculoskeletal Disorders. 2014;15(1):162. Jones A, Doherty M. Osteoarthritis. Oxford: Clinical Pub.; 2013. Pratt JH, Eckert GJ, Newman S, Ambrosius WT. Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects. Hypertension. 2001;38(5):1124–9. Acknowledgement We thank Professor Dr. Marina Backhaus for providing ultrasonography training course in the rheumatologic department at the Charite Universitatsmedizin, Berlin, Germany, and also Dr. May Hasan for recruiting patients for the study at the Sohag University in Egypt Disclosure of Interest None declared |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|